NDAORALCAPSULEPriority Review
Approved
Nov 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARVON COMPOUND-65 is an oral capsule combining propoxyphene hydrochloride (an opioid analgesic) with aspirin and caffeine for pain relief. It was designed to treat moderate pain by leveraging the synergistic effects of an opioid, NSAID, and stimulant. The product represents a combination-therapy approach common in legacy pain management.
LOE Approaching
Product is in late-stage lifecycle with limited competitive pressure (30/100), suggesting a mature, potentially declining franchise with minimal team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Only 1 linked job currently available, indicating a minimal active team focused on this legacy product. Career opportunities are constrained, with roles likely focused on regulatory compliance, supply chain, or internal brand maintenance rather than growth initiatives.
DOCTORA
1 open roles linked to this drug
Worked on DARVON COMPOUND-65 at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.